Compare Abeona Therapeutics Inc (ABEO) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Wynn Resorts, Limited — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while Wynn Resorts, Limited trades at $98.18 (market cap $10.00B). The key difference: Wynn Resorts, Limited is far larger — about 26.8× Abeona Therapeutics Inc's market cap, and Wynn Resorts, Limited pays a 1.04% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | WYNN | |
|---|---|---|
Market Cap | $373.32M | $10.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $133.34 |
52-Week Low | $4.17 | $94.78 |
Enterprise Value | $228.22M | $20.36B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Wynn Resorts (WYNN) trades at $96.35, up 0.46% on the day, with a bearish technical signal and recent earnings misses. Revenue reached $7.14B in 2025, but net income declined to $327M, reflecting margin pressure. Analyst consensus remains strongly bullish with a $136.22 price target, though high debt and competitive headwinds persist. The company announced Q2 2026 earnings for August 4, 2026, with investor focus on Macau and Las Vegas performance.
The stock presents a contrarian opportunity given analyst optimism amid technical weakness. Upside hinges on earnings recovery and debt management, but risks include geopolitical tensions in Macau and sustained margin compression. Current valuation at P/E 27.47 may limit near-term gains without profit improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
